

- Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. *J Natl Cancer Inst* 2000;92:1240-1251.
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005;105:3768-3785.
- Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. *J Cutan Pathol* 2006;33:18-26.
- Bunn PA Jr, Huberman MS, Whang-Peng J, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. *Ann Intern Med* 1980;93:223-230.
- Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. *Hum Pathol* 1985;16:1098-1109.
- Schechter GP, Bunn PA, Fischmann AB, et al. Blood and lymph node T lymphocytes in cutaneous T cell lymphoma: evaluation by light microscopy. *Cancer Treat Rep* 1979;63:571-574.
- Toro JR, Stoll HL Jr, Stomper PC, et al. Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome. *J Am Acad Dermatol* 1997;37:58-67.
- Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. *J Am Acad Dermatol* 2002;46:95-106.
- Abrams JT, Balin BJ, Vonderheid EC. Association between Sezary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. *Ann N Y Acad Sci* 2001; 941:69-85.
- Rosler MJ, Rappi G, Muche M, et al. No evidence of skin infection with Chlamydia pneumoniae in patients with cutaneous T cell lymphoma. *Clin Microbiol Infect* 2003;9:721-723.
- Pancake BA, Wassef EH, Zucker-Franklin D. Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus. *Blood* 1996;88:3004-3009.
- Pancake BA, Zucker-Franklin D. The difficulty of detecting HTLV-I proviral sequences in patients with mycosis fungoides. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13:314-319.
- Zucker-Franklin D, Coutavas EE, Rush MG, et al. Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides. *Proc Natl Acad Sci USA* 1991;88:7630-7634.
- Zucker-Franklin D, Hooper WC, Evatt BL. Human lymphotropic retroviruses associated with mycosis fungoides: evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease. *Blood* 1992;80:1537-1545.
- Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. *JAMA* 1992;267:1354-1358.
- Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. *Blood* 2003;102:4059-4066.
- Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. *N Engl J Med* 2004;350:1978-1988.
- Picker LJ, Kishimoto TK, Smith CW, et al. ELAM-1 is an adhesion molecule for skin-homing T cells. *Nature* 1991;349:796-799.
- Berg EL, Yoshino T, Rott LS, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. *J Exp Med* 1991;174:1461-1466.
- Nickoloff BJ, Griffiths CE. T lymphocytes and monocytes bind to keratinocytes in frozen sections of biopsy specimens of normal skin treated with gamma interferon. *J Am Acad Dermatol* 1989;20:736-743.
- Nickoloff BJ, Griffiths CE, Baadsgaard O, et al. Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule-1 (ICAM-1) in Sezary syndrome. *JAMA* 1989;261:2217-2221.
- Mao X, Orchard G, Lillington DM, et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. *Blood* 2003;101:1513-1519.
- Scarisbrick JJ, Woolford AJ, Russell-Jones R, et al. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. *Blood* 2000;95:2937-2942.
- Lin WM, Lewis JM, Filler RB, et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. *J Invest Dermatol* 2012;132:188-197.
- Karenko L, Hahtola S, Paivinen S, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. *Cancer Res* 2005;65:8101-8110.
- Mao X, Lillington DM, Czepulkowski B, et al. Molecular cytogenetic characterization of Sezary syndrome. *Genes Chromosomes Cancer* 2003;36:250-260.
- Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. *J Am Acad Dermatol* 2005;53:1053-1063.
- Simon M, Flaig MJ, Kind P, et al. Large plaque parapsoriasis: clinical and genotypic correlations. *J Cutan Pathol* 2000;27:57-60.
- Wood GS, Tung RM, Haeffner AC, et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). *J Invest Dermatol* 1994;103:34-41.
- Duangurai K, Piamphongsant T, Himmungnan T. Sezary cell count in exfoliative dermatitis. *Int J Dermatol* 1988;27:248-252.
- Duncan SC, Winkelmann RK. Circulating Sezary cells in hospitalized dermatology patients. *Br J Dermatol* 1978;99:171-178.
- Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. *Br J Dermatol* 2002;147:464-475.
- Scarisbrick JJ, Whittaker S, Evans AV, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. *Blood* 2001;97:624-630.
- Lynch JW Jr, Linoilla I, Sausville EA, et al. Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides. *Blood* 1992;79:3293-3299.
- Graham SJ, Sharpe RW, Steinberg SM, et al. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome. *Cancer* 1993;72:726-734.
- Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. *J Am Acad Dermatol* 1999;40:914-924.
- Salhany KE, Greer JP, Cousar JB, et al. Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases. *Am J Clin Pathol* 1989;92:747-754.
- Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. *Ann Intern Med* 1988;109:372-382.
- Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. *Cancer Treat Rep* 1979;63:725-728.
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood* 2007;110:1713-1722.
- Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer staging proposal. *J Clin Oncol* 2010;28:4730-4739.
- Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. *Arch Dermatol* 1995;131:1003-1008.
- Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. *Blood* 1998;92:1150-1159.
- Dmitrovsky E, Matthews MJ, Bunn PA, et al. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. *J Clin Oncol* 1987;5:208-215.
- Olsen EA, Rook AH, Zic J, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). *J Am Acad Dermatol* 2011;64:352-404.
- Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). *Arch Dermatol* 2002;138:42-48.
- Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). *Blood* 1996;88:1383-1389.
- Kumar R, Xiu Y, Zhuang HM, et al. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. *Br J Dermatol* 2006;155:357-363.
- Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. *Arch Dermatol* 2006;142:577-584.
- Kim YH, Liu HL, Mraz-Cernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. *Arch Dermatol* 2003;139:857-866.
- Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. *Int J Radiat Oncol Biol Phys* 1995;33:781-796.
- Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). *Int J Radiat Oncol Biol Phys* 1998;40:109-115.
- Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. *J Clin Oncol* 1995;13:257-263.
- Stadler R, Otte HC, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. *Blood* 1998;92:3578-3581.

55. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. *J Am Acad Dermatol* 2002;47:364–370.
56. Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). *Cancer* 1999;85:1985–1995.
57. Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. *Hematol Oncol Clin North Am* 2003;17:1421–1434.
58. Harrison C, Young J, Navi D, et al. Revisiting low dose total skin electron beam therapy in mycosis fungoides. *Int J Radiat Oncol Biol Phys* 2011;81:e651–e657.
59. Licata AG, Wilson LD, Braverman IM, et al. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. *Arch Dermatol* 1995;131:432–435.
60. Wilson LD, Quiros PA, Kolenik SA, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. *J Am Acad Dermatol* 1996;35:69–73.
61. Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. *Int J Radiat Oncol Biol Phys* 1995;32:1445–1449.
62. Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). *Int J Radiat Oncol Biol Phys* 1997;38:1027–1035.
63. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. *Int J Radiat Oncol Biol Phys* 1999;43:951–958.
64. Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. *Int J Radiat Oncol Biol Phys* 1995;32:987–995.
65. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. *J Am Acad Dermatol* 2000;43:54–60.
66. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. *Hematol Oncol Clin North Am* 1995;9:1089–1107.
67. Foss FM, Higgins B. Intermediate dose interleukin-2 demonstrates activity in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood* 2004;104:2642.
68. Duvic M, Sherman ML, Wood GS, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. *J Am Acad Dermatol* 2006;55:807–813.
69. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. *Int J Cancer* 2001;91:438–447.
70. Girardi M, Berger C, Hanlon D, et al. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization. *Technol Cancer Res Treat* 2002;1:65–69.
71. Knobler R, Duvic M, Querfeld C, et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatol Photoimmunol Photomed* 2012;28:250–257.
72. Dani T, Knobler R. Extracorporeal photoinmunotherapy-photopheresis. *Front Biosci (Landmark Ed)* 2009;14:4769–4777.
73. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. *J Am Acad Dermatol* 1996;35:573–579.
74. Talpur R, Demierre MF, Geskin L, et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. *Clin Lymphoma Myeloma Leuk* 2011;11:219–227.
75. Suchin KR, Cucchiara AJ, Gottlieb SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. *Arch Dermatol* 2002;138:1054–1060.
76. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. *J Am Acad Dermatol* 2002;47:672–684.
77. Bisaccia E, Gonzalez J, Palangio M, et al. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. *J Am Acad Dermatol* 2000;43:263–271.
78. Tsiirigotis P, Pappa V, Papageorgiou S, et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sezary syndrome. *Br J Dermatol* 2007;156:1379–1381.
79. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. *J Cutan Med Surg* 2003;7:3–7.
80. Girardi M, Berger CL, Wilson LD, et al. Transimmunization for cutaneous T cell lymphoma: a Phase I study. *Leuk Lymphoma* 2006;47:1495–1503.
81. Richardson SK, Newton SB, Bach TL, et al. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. *Am J Hematol* 2007;82:792–797.
82. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. *J Clin Oncol* 2001;19:2456–2471.
83. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. *Cancer* 2007;109:1799–1803.
84. Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). *Br J Dermatol* 2012;167:678–687.
85. Straus DJ, Duvic M, Horwitz SM, et al. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. *Ann Oncol* 2014;25:206–210.
86. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. *J Clin Oncol* 2009;27:5410–5417.
87. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. *J Clin Oncol* 2010;28:4485–4491.
88. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoyl-anilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). *Blood* 2007;109:31–39.
89. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* 2007;25:3109–3115.
90. Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. *Blood* 2009;Abstract 920.
91. Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. *Eur J Cancer* 2013;49:386–394.
92. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol* 2001;19:376–388.
93. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. *Clin Lymphoma* 2001;1:298–302.
94. Negro-Vilar A, Prince H, Duvic M, et al. Efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials. *J Clin Oncol* 2008;26:8551.
95. Foss F, Demierre MF, DiVenuti G. A phase-I trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood* 2005;106:454–457.
96. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. *Eur J Haematol* 2003;71:250–256.
97. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. *Blood* 2003;101:4267–4272.
98. Rider DA, Havenith CE, de Ridder R, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. *Cancer Res* 2007;67:9945–9953.
99. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. *Blood* 2007;109:4655–4662.
100. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. *Clin Cancer Res* 2004;10:7529–7539.
101. Duvic M, Pinter-Brown L, Foss F, et al. Correlation of target molecule expression and overall response in refractory cutaneous T-cell lymphoma patients dosed with mogamulizumab (KW0761), a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4). *Blood* 2012;120.
102. Duvic M, Tetzlaff M, Clos A, et al. Phase II trial of brentuximab vedotin For CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. *Blood* 2013;122:367.
103. Koizumi K, Sawada K, Nishio M, et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. *Bone Marrow Transplant* 1997;20:171–173.
104. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. *J Clin Oncol* 1999;17:3117–3121.
105. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. *J Clin Oncol* 1992;10:1907–1913.
106. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. *J Clin Oncol* 1994;12:2051–2059.
107. Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. *Br J Dermatol* 2001;144:1010–1015.

108. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. *Cancer* 2005;104:2437–2441.
109. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. *Arch Dermatol* 2008;144:727–733.
110. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. *J Clin Oncol* 2012;30:4091–4097.
111. Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. *Cancer Chemother Pharmacol* 2009;64:993–999.
112. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol* 2011;29:1182–1189.
113. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood* 2012;119:4115–4122.
114. Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. *J Clin Oncol* 2005;23:6163–6171.
115. Paralkar VR, Nasta SD, Morrissey K, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. *Bone Marrow Transplant* 2012;47:940–945.
116. Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 2010;28:4492–4499.
117. Kadin ME. Pathobiology of CD30+ cutaneous T-cell lymphomas. *J Cutan Pathol* 2006;33:10–17.
118. Smith BD, Glusac EJ, McNiff JM, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. *J Clin Oncol* 2004;22:634–639.
119. Smith BD, Smith GL, Cooper DL, et al. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. *J Clin Oncol* 2005;23:3390–3395.
120. Child FJ, Scarisbrick JJ, Calonje E, et al. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. *J Invest Dermatol* 2002;118:941–948.
121. Eich HT, Eich D, Micke O, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. *Int J Radiat Oncol Biol Phys* 2003;55:899–906.
122. Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases. *Radiother Oncol* 1999;52:15–18.
123. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. *Eur J Dermatol* 2003;13:49–52.
124. Piccinno R, Caccialanza M, Berti E, et al. Radiotherapy of cutaneous B cell lymphomas: our experience in 31 cases. *Int J Radiat Oncol Biol Phys* 1993;27:385–389.
125. Rijlaarsdam JU, Toonstra J, Meijer OW, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. *J Clin Oncol* 1996;14:549–555.